Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Other financing activities (2020 - 2024)

RxSight posted quarterly Other financing activities of -$768000.0 for Q4 2024, down 2972.0% year-on-year from $26740.9 in Q1 2024, and down 211.63% on a QoQ basis from $688000.0 in Q3 2024.

RxSight (RXST) has 5 years of Other financing activities data on file, last reported at -$768000.0 in Q4 2024.

  • For the quarter ending Q4 2024, Other financing activities fell 2972.0% year-over-year to -$768000.0; the trailing twelve-month figure through Dec 2025 stood at -$80000.0 (changed N/A YoY), and the FY2023 full-year result was $622000.0, up 328.97% from the prior year.
  • Other financing activities for Q4 2024 stood at -$768000.0, down from $688000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $688000.0 in Q3 2024 and bottomed at -$768000.0 in Q4 2024.
  • The 5-year median for Other financing activities is $62500.0 (2023), against an average of $113285.7.
  • The widest annual swing landed in 2023, when Other financing activities soared 2150.0%; it then plunged 2972.0% in 2024.
  • A 5-year view of Other financing activities shows it stood at $687000.0 in 2020, then slumped by 116.01% to -$110000.0 in 2021, then surged by 100.91% to $1000.0 in 2022, then slumped by 2600.0% to -$25000.0 in 2023, then slumped by 2972.0% to -$768000.0 in 2024.
  • The last three Other financing activities figures came in at -$768000.0 (Q4 2024), $688000.0 (Q3 2024), and $80000.0 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 RxSight 215.82 Mn -2.06 Mn 23.50 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -768,000.00
Dec 31, 2024 -768,000.00
Sep 30, 2024 688,000.00
Sep 30, 2024 688,000.00
Jun 30, 2024 80,000.00
Jun 30, 2024 80,000.00
Dec 31, 2023 -25,000.00
Dec 31, 2023 -25,000.00
Sep 30, 2023 45,000.00
Sep 30, 2023 45,000.00
Jun 30, 2023 372,000.00
Jun 30, 2023 372,000.00
Mar 31, 2023 230,000.00
Mar 31, 2023 230,000.00
Dec 31, 2022 1,000.00
Dec 31, 2022 1,000.00
Sep 30, 2022 2,000.00
Sep 30, 2022 2,000.00
Jun 30, 2022 142,000.00
Jun 30, 2022 142,000.00
Dec 31, 2021 -110,000.00
Dec 31, 2021 -110,000.00
Jun 30, 2021 202,000.00
Jun 30, 2021 202,000.00
Mar 31, 2021 40,000.00
Mar 31, 2021 40,000.00
Dec 31, 2020 687,000.00
Dec 31, 2020 687,000.00